



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2012	2011	% Change		
			Reported	Operational ⁽¹⁾	Currency
CONSUMER SEGMENT ⁽²⁾					
<u>BABY CARE</u>					
US	\$ 99	105	-5.7%	-5.7%	-
Intl	441	456	-3.3%	-0.4%	-2.9%
WW	<u>540</u>	<u>561</u>	-3.7%	-1.4%	-2.3%
<u>ORAL CARE</u>					
US	155	163	-4.9%	-4.9%	-
Intl	232	228	1.8%	4.7%	-2.9%
WW	<u>387</u>	<u>391</u>	-1.0%	0.7%	-1.7%
<u>OTC/NUTRITIONALS</u>					
US	381	397	-4.0%	-4.0%	-
Intl	723	732	-1.2%	1.7%	-2.9%
WW	<u>1,104</u>	<u>1,129</u>	-2.2%	-0.3%	-1.9%
<u>SKIN CARE</u>					
US	453	426	6.3%	6.3%	-
Intl	454	473	-4.0%	-1.7%	-2.3%
WW	<u>907</u>	<u>899</u>	0.9%	2.1%	-1.2%
<u>WOMEN'S HEALTH</u>					
US	93	125	-25.6%	-25.6%	-
Intl	316	334	-5.4%	-1.7%	-3.7%
WW	<u>409</u>	<u>459</u>	-10.9%	-8.2%	-2.7%
<u>WOUND CARE/OTHER</u>					
US	135	129	4.7%	4.7%	-
Intl	113	114	-0.9%	1.7%	-2.6%
WW	<u>248</u>	<u>243</u>	2.1%	3.3%	-1.2%
<u>TOTAL CONSUMER</u>					
US	1,316	1,345	-2.2%	-2.2%	-
Intl	2,279	2,337	-2.5%	0.4%	-2.9%
WW	<u>\$ 3,595</u>	<u>3,682</u>	-2.4%	-0.6%	-1.8%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2012	2011	% Change		
			Reported	Operational ⁽¹⁾	Currency
<u>PHARMACEUTICAL SEGMENT</u> ^{(2) (4)}					
<u>IMMUNOLOGY</u>					
US	\$ 1,453	1,436	1.2%	1.2%	-
Intl	442	144	*	*	-2.2%
WW	<u>1,895</u>	<u>1,580</u>	19.9%	20.5%	-0.6%
<u>REMICADE</u>					
US	882	788	11.9%	11.9%	-
US Exports ⁽³⁾	378	490	-22.9%	-22.9%	-
Intl	261	7	*	*	-2.2%
WW	<u>1,521</u>	<u>1,285</u>	18.4%	18.4%	0.0%
<u>SIMPONI</u>					
US	64	53	20.8%	20.8%	-
Intl	52	42	23.8%	25.0%	-1.2%
WW	<u>116</u>	<u>95</u>	22.1%	22.6%	-0.5%
<u>STELARA</u>					
US	129	105	22.9%	22.9%	-
Intl	92	61	50.8%	53.9%	-3.1%
WW	<u>221</u>	<u>166</u>	33.1%	34.8%	-1.7%
<u>OTHER IMMUNOLOGY</u>					
US	-	-	-	-	-
Intl	37	34	8.8%	10.7%	-1.9%
WW	<u>37</u>	<u>34</u>	8.8%	10.7%	-1.9%
<u>INFECTIOUS DISEASES</u>					
US	242	624	-61.2%	-61.2%	-
Intl	513	307	67.1%	70.5%	-3.4%
WW	<u>755</u>	<u>931</u>	-18.9%	-17.0%	-1.9%
<u>INTELENCE</u>					
US	43	38	13.2%	13.2%	-
Intl	37	31	19.4%	23.0%	-3.6%
WW	<u>80</u>	<u>69</u>	15.9%	17.8%	-1.9%
<u>LEVAQUIN/FLOXIN</u>					
US	18	422	-95.7%	-95.7%	-
Intl	11	12	-8.3%	-4.8%	-3.5%
WW	<u>29</u>	<u>434</u>	-93.3%	-93.2%	-0.1%
<u>PREZISTA</u>					
US	160	126	27.0%	27.0%	-
Intl	164	140	17.1%	20.9%	-3.8%
WW	<u>324</u>	<u>266</u>	21.8%	24.1%	-2.3%
<u>OTHER INFECTIOUS DISEASES</u>					
US	21	38	-44.7%	-44.7%	-
Intl	301	124	*	*	-3.2%
WW	<u>322</u>	<u>162</u>	98.8%	*	-3.0%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	<u>2012</u>	<u>2011</u>	<u>% Change</u>		
			<u>Reported</u>	<u>Operational ⁽¹⁾</u>	<u>Currency</u>
<u>NEUROSCIENCE</u>					
US	\$ 674	688	-2.0%	-2.0%	-
Intl	973	1,057	-7.9%	-5.8%	-2.1%
WW	<u>1,647</u>	<u>1,745</u>	-5.6%	-4.3%	-1.3%
<u>CONCERTA/METHYLPHENIDATE</u>					
US	197	254	-22.4%	-22.4%	-
Intl	111	108	2.8%	5.8%	-3.0%
WW	<u>308</u>	<u>362</u>	-14.9%	-14.0%	-0.9%
<u>INVEGA</u>					
US	69	69	0.0%	0.0%	-
Intl	52	51	2.0%	3.7%	-1.7%
WW	<u>121</u>	<u>120</u>	0.8%	1.5%	-0.7%
<u>INVEGA SUSTENNA</u>					
US	100	65	53.8%	53.8%	-
Intl	61	-	100.0%	100.0%	-
WW	<u>161</u>	<u>65</u>	*	*	-
<u>RISPERDAL CONSTA</u>					
US	113	114	-0.9%	-0.9%	-
Intl	248	290	-14.5%	-11.8%	-2.7%
WW	<u>361</u>	<u>404</u>	-10.6%	-8.7%	-1.9%
<u>OTHER NEUROSCIENCE</u>					
US	195	186	4.8%	4.8%	-
Intl	501	608	-17.6%	-16.2%	-1.4%
WW	<u>696</u>	<u>794</u>	-12.3%	-11.2%	-1.1%
<u>ONCOLOGY</u>					
US	107	64	67.2%	67.2%	-
Intl	489	375	30.4%	33.7%	-3.3%
WW	<u>596</u>	<u>439</u>	35.8%	38.5%	-2.7%
<u>DOXIL/CAELYX</u>					
US	7	64	-89.1%	-89.1%	-
Intl	17	75	-77.3%	-76.2%	-1.1%
WW	<u>24</u>	<u>139</u>	-82.7%	-82.1%	-0.6%
<u>VELCADE</u>					
US	-	-	-	-	-
Intl	353	280	26.1%	29.3%	-3.2%
WW	<u>353</u>	<u>280</u>	26.1%	29.3%	-3.2%
<u>ZYTIGA</u>					
US	100	-	100.0	100.0	-
Intl	100	5	*	*	-1.9%
WW	<u>200</u>	<u>5</u>	*	*	-1.9%
<u>OTHER ONCOLOGY</u>					
US	-	-	-	-	-
Intl	19	15	26.7%	29.7%	-3.0%
WW	<u>19</u>	<u>15</u>	26.7%	29.7%	-3.0%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	<u>2012</u>	<u>2011</u>	<u>% Change</u>		
			<u>Reported</u>	<u>Operational ⁽¹⁾</u>	<u>Currency</u>
<u>TOTAL OTHER</u>					
US	\$ 550	579	-5.0%	-5.0%	-
Intl	690	785	-12.1%	-10.0%	-2.1%
WW	<u>1,240</u>	<u>1,364</u>	-9.1%	-7.9%	-1.2%
<u>ACIPHEX/PARIET</u>					
US	96	109	-11.9%	-11.9%	-
Intl	126	130	-3.1%	-	-3.1%
WW	<u>222</u>	<u>239</u>	-7.1%	-5.4%	-1.7%
<u>PROCRIT/EPREX</u>					
US	204	190	7.4%	7.4%	-
Intl	172	207	-16.9%	-14.0%	-2.9%
WW	<u>376</u>	<u>397</u>	-5.3%	-3.8%	-1.5%
<u>OTHER</u>					
US	250	280	-10.7%	-10.7%	-
Intl	392	448	-12.5%	-11.1%	-1.4%
WW	<u>642</u>	<u>728</u>	-11.8%	-11.0%	-0.8%
<u>TOTAL PHARMACEUTICAL</u>					
US	3,026	3,391	-10.8%	-10.8%	-
Intl	3,107	2,668	16.5%	19.6%	-3.1%
WW	<u>\$ 6,133</u>	<u>6,059</u>	1.2%	2.6%	-1.4%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2012	2011	% Change		
			Reported	Operational ⁽¹⁾	Currency
<u>MEDICAL DEVICES AND DIAGNOSTICS</u> ⁽²⁾⁽⁴⁾					
<u>CARDIOVASCULAR CARE</u>					
US	\$ 176	242	-27.3%	-27.3%	-
Intl	306	393	-22.1%	-21.2%	-0.9%
WW	<u>482</u>	<u>635</u>	-24.1%	-23.5%	-0.6%
<u>DIABETES CARE</u>					
US	352	311	13.2%	13.2%	-
Intl	318	326	-2.5%	0.2%	-2.7%
WW	<u>670</u>	<u>637</u>	5.2%	6.6%	-1.4%
<u>DIAGNOSTICS</u>					
US	253	265	-4.5%	-4.5%	-
Intl	259	256	1.2%	2.5%	-1.3%
WW	<u>512</u>	<u>521</u>	-1.7%	-1.1%	-0.6%
<u>GENERAL SURGERY</u>					
US	593	596	-0.5%	-0.5%	-
Intl	1,032	1,025	0.7%	2.6%	-1.9%
WW	<u>1,625</u>	<u>1,621</u>	0.2%	1.4%	-1.2%
<u>INFECTION PREVENTION/OTHER</u>					
US	116	95	22.1%	22.1%	-
Intl	128	121	5.8%	6.5%	-0.7%
WW	<u>244</u>	<u>216</u>	13.0%	13.4%	-0.4%
<u>ORTHOPAEDICS</u>					
US	783	811	-3.5%	-3.5%	-
Intl	710	692	2.6%	4.1%	-1.5%
WW	<u>1,493</u>	<u>1,503</u>	-0.7%	0.0%	-0.7%
<u>SPECIALTY SURGERY</u>					
US	327	296	10.5%	10.5%	-
Intl	301	281	7.1%	9.3%	-2.2%
WW	<u>628</u>	<u>577</u>	8.8%	9.9%	-1.1%
<u>VISION CARE</u>					
US	277	256	8.2%	8.2%	-
Intl	480	466	3.0%	2.6%	0.4%
WW	<u>757</u>	<u>722</u>	4.8%	4.5%	0.3%
<u>TOTAL MEDICAL DEVICES AND DIAGNOSTICS</u>					
US	2,877	2,872	0.2%	0.2%	-
Intl	3,534	3,560	-0.7%	0.7%	-1.4%
WW	<u>\$ 6,411</u>	<u>6,432</u>	-0.3%	0.5%	-0.8%

* Percentage greater than 100%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Reported as U.S. sales

(4) Prior year amounts have been reclassified to conform to current year product disclosure